Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 23, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 212 | $68.54 | $14,530.48 |
DisclosureSEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,802 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,629 | $69.82 | $113,736.78 |
DisclosureSEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,014 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.52 to $70.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 588 | $68.54 | $40,301.52 |
DisclosureSEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,643 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,081 | $69.36 | $213,698.16 |
DisclosureSEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,231 F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,813 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001578852-26-000008 · form4-02192026_050201.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,501 Underlying: Common Stock · 2,813 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2 | $70.13 | $140.26 |
DisclosureSEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,312 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,811 | $69.29 | $194,774.19 |
DisclosureSEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,314 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.84 to $69.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,813 | $25.69 | $72,265.97 |
DisclosureSEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 107 | $79.52 | $8,508.64 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,312 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.35 to $79.60 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 686 | $78.71 | $53,995.06 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,419 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.23 to $79.21 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,521 | $77.46 | $117,816.66 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,105 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.12 to $78.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,286 | $76.45 | $98,314.70 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,626 F4 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 265 | $77.07 | $20,423.55 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.99 to $77.23 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,482 | $76.56 | $190,021.92 |
DisclosureSEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,177 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.95 to $76.92 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 751 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · derivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 751 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,625 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · derivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 751 Underlying: Common Stock · 2,627 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11 | $78.98 | $868.78 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,659 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 269 | $77.92 | $20,960.48 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,670 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.54 to $78.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 471 | $77.10 | $36,314.10 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,939 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.54 to $77.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 751 | $38.10 | $28,613.10 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 38 | $78.60 | $2,986.80 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,659 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 949 | $77.91 | $73,936.59 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,697 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.58 to $78.54 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,638 | $77.11 | $126,306.18 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,646 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.56 to $77.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,625 | $38.10 | $100,012.50 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,503 | $77.48 | $116,452.44 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,659 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,739 | $76.95 | $133,816.05 |
DisclosureSEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,162 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 3, 2025 grant of 18,000 RSUs. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,266 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · derivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,063 Underlying: Common Stock · 2,266 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F7 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 108 | $76.79 | $8,293.32 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,901 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,035 | $76.10 | $78,763.50 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,009 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,123 | $74.92 | $84,135.16 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,044 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,266 | $39.42 | $89,325.72 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2036-01-01 F6 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,901 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,812 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001578852-25-000010 · form4-11192025_051101.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,314 Underlying: Common Stock · 2,812 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F5 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 192 | $77.18 | $14,818.56 |
DisclosureSEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 777 | $76.53 | $59,463.81 |
DisclosureSEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,093 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.08 to $77.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,843 | $75.64 | $139,404.52 |
DisclosureSEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,870 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.06 to $76.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,812 | $25.69 | $72,240.28 |
DisclosureSEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,375 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000008 · form4-10092025_051001.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,376 Underlying: Common Stock · 3,375 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F5 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 312 | $64.97 | $20,270.64 |
DisclosureSEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,306 | $63.80 | $83,322.80 |
DisclosureSEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,213 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,757 | $62.89 | $110,497.73 |
DisclosureSEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,519 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,375 | $38.10 | $128,587.50 |
DisclosureSEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,266 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 19 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,329 Underlying: Common Stock · 2,266 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,266 | $65.07 | $147,448.62 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F12 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.72 to $65.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,266 | $39.42 | $89,325.72 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,265 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 18 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,595 Underlying: Common Stock · 2,265 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,266 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,860 Underlying: Common Stock · 2,266 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,124 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,126 Underlying: Common Stock · 18,124 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 877 | $66.67 | $58,469.59 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.